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Latent TB infection (LTBI) constitutes part of the tuberculosis (TB) disease spectrum (1, 2). The 
diagnosis and treatment of LTBI is important as global eradication targets will not be attainable 
without treating LTBI (3).These considerations also apply to drug-resistant TB, which threatens to 
derail control efforts (4). The WHO has recently recommended that close contacts of index cases of 
TB, even in TB endemic countries, should be considered for LTBI treatment (even if they are HIV-
uninfected or not children) (5). However, the diagnosis of LTBI is challenging.  Unlike with active TB, 
in humans there is no microbiological or histopathological reference standard for LTBI, and one can 
only infer the potential presence of LTBI using immunodiagnostic tests, which enumerate the 
magnitude of relatively antigen-specific Th1 effector T-cell responses (6). However, it is 
epidemiologically well-recognised that only a small proportion of individuals with presumed LTBI (~5 
to 10%) will progress to active TB over a lifetime (7).Thus, the more important public health question 
is whether, and how, we can accurately target treatment by identifying individuals who are most 
likely to progress to active TB.   This state is broadly defined as  ‘incipient TB’ and  is characterised by 
a lack of TB-related symptoms and appropriate chest radiographic abnormalities at the time of 
testing,  and lack of any microbiological evidence of active TB, but a high likelihood of progression to 
active TB in the short-term,  with the potential for perpetuating the transmission cycle (2). The 
duration from initial exposure to incipient TB or active disease is variable and will depend of several 
host, mycobacterial, and environmental factors. Epidemiological data suggest that of those infected, 
~ 5% will progress to active TB over a five year period with the highest risk being within the first 2 
years of exposure (8, 9).  Biomarkers to identify incipient TB has remained one of the ‘Holy Grails’ of 
TB research.
Given these considerations it has often been asked whether a higher magnitude of the IFN-y release 
assay (IGRA) response, or larger TST induration diameter, reflecting a higher burden of circulating 
effector T cells and inferring a higher burden of Mycobacterium tuberculosis, predicts a higher 
likelihood of incipient TB.  Indeed, serial IGRA responses increasing in magnitude over time was 
associated with the development of active disease in several reports suggesting that antigen-driven 
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T-cell responses could be a marker of incipient TB (10). However, there are limited and conflicting 
data regarding this point. Zellweger and Haldar found no association between the magnitude of the 
IFN- γ response and progression to active TB (11, 12). By contrast, Winje et al interrogated a large 
population-based cohort using QuantiFERON Gold In-Tube (QFT-GIT) and found that a quantitative 
IGRA readout > 4.0 IU/L was highly associated (> 30 fold risk compared to QFT negativity) with the 
development of active TB (13). Using a different metric Andrews and co-workers from South Africa 
found that QFT conversion at interferon-γ values higher than 4·00 IU/L (but not below this threshold) 
was associated with substantially increased risk (42 fold higher risk than non-converters) of 
developing active TB over a, ~2 year period (14). However, although these data collectively 
suggested that the magnitude of the T cell response was associated with higher rates of downstream 
active TB,  there remained several unanswered questions. Did this relationship hold true for  other 
immunodiagnostic readouts (like T-SPOT-TB and the TST), what are the implications for clinical 
practice, and is this relationship meaningful and clinically useful? 
The study by Gupta and co-workers (15), here, provides answers to some of these questions. Their 
findings were based on the results of the prospective UK-based PREDICT study that evaluated 3 
immunodiagnostic tests (T-SPOT TB, QuantiFERON TB Gold, and TST) in almost 10 000 participants 
who were at high risk of LTBI (close contacts of active TB cases or  recent migrants) sequentially 
recruited from 54 centres in the UK (16). They found that, although the magnitude of the IGRA (both 
QFT-GIT & T-SPOT) and the TST response was a biomarker of incipient TB, the threshold-specific PPV 
for all 3 immunodiagnostic tests for active TB over a median follow up of ~3 years was poor at < 5%.  
This is because there were many non-progressors who had a magnitude of response at or above the 
threshold identifying incipient TB. Moreover, using this higher threshold in clinical practice would 
result in a substantial drop in test sensitivity to detect active TB cases making the usefulness of such 
an approach redundant. This is because IGRAs and TSTs are simply poor tests of incipient TB. This is 
not surprising as only a small proportion of those with LTBI (~5%) will progress to active disease. 
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The authors must be commended on undertaking such a challenging study both in terms of 
recruitment and analysis. The findings are helpful to clinicians and public health physicians who are 
using immunodiagnostics tests in screening programmes. It suggests that alternative biomarkers of 
incipient TB are urgently needed. A weakness of the study though, despite the drawbacks of the 
IGRAs, was the lack of serial testing (discussed below). Such an approach would have only been 
feasible if the TST was not performed at baseline (as tuberculin contains RD-1 antigen and can boost 
downstream IGRA responses (17).To try and circumvent the poor predictive value and specificity, 
alternative immunodiagnostic readouts have been investigated including: (i) different cytokine 
readouts e.g. combination of IL-2/ IFN-y, (ii) T cell responses to alternative antigens e.g. HBHA  and 
Ag85a (18-20), (iii) cell activation markers e.g. CD4+HLA-DR+ T cells (21), and (iv) readouts from 
alternative compartments including RD-1-based skin tests that are being commercialised (22). 
Other investigators have uncovered biosignatures of incipient TB. Several studies have identified 
blood-based transcriptional signatures associated with progression to active TB (23-26) with a 
positive predictive value ~10 fold higher than the IGRAs. These genomic biosignatures, consisting of 
3 to 16 gene transcripts, were able to predict TB progression in participants with LTBI with 
reasonable accuracy, though performance was variable when validated against other cohorts. 
Suliman et al (27) derived a 4-gene signature, which correlated with TB disease progression and 
performed well when validated against other transcriptomic signatures. However, using a RT-PCR 
based readouts may not be user-friendly or cost-effective for TB-endemic settings. Very recently a 3 
to 5 protein biosignature of incipient TB was derived and validated (28), and a novel ultrasensitive 
phage-based amplification assay for incipient TB was described (29). These data suggest that a point-
of-care assay may be a realistic goal once better biomarkers are developed and validated.
Another broader issue raised by this study is the ambiguous and confusing interpretation of IGRA 
readouts. On the one hand, positive IGRA responses are often interpreted as a marker of LTBI and 
hence ‘protection’ given that ~95% never progress to active disease, and serial IGRA responses often 
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decrease during the course of successful TB treatment (30). By contrast, the work of Gupta and 
others suggest that IGRAs are a biomarker of incipient TB and hence TB risk.  Which is it, protection 
or risk? This answer is both depending on the clinical context. Thus the conundrum can be resolved 
by recognising that TB is a spectrum of infection, which is a dynamic interplay between host and 
pathogen at the level of the granuloma, and this may change over time reflecting timepoint-specific 
host immunity and mycobacterial disease burden (and hence changing levels of TB-specific effector 
T-cells in blood).  A temporal compartment-specific effect may also influence interpretation due to 
translocation of antigen-specific T cells from the blood to the disease site, e.g the lung (31). Thus, 
serial measurements may often be required to determine whether IGRA responses are stable, 
increase in magnitude over time (conversion), or reduce in magnitude  over time (reversion), 
possibly suggesting clearance of infection (32). This concept has been well outlined in a recent 
review (6). Thus, IGRA readouts can be a marker of protection or susceptibility depending on the 
context. This will explain why patients with stable persistently positive IGRA responses remain 
asymptomatic and do not progress to active TB over many years, whilst those with increasing 
counts/ responses progress to active TB, whilst others may revert to presumably clear their 
infection. Thus, selecting vaccine candidates simply on their ability to induce or drive antigen-specific 
IFN-y responses is counterintuitive;  rather, selection based on preventing sustained conversion 
seems more logical and is an approach that has recently been used (33). 
For now, the findings of Gupta and colleagues is clinically useful and points us in the right direction. 
The bottom-line is that better biomarkers of incipient TB are required, and nascent biomarker 
signatures require urgent prospective clinical validation. It is hoped that these resource-intensive 
and challenging prospective validation studies [like the CORTIS study (34)] will be fruitful rather than 
futile as TB remains the foremost infectious diseases killer globally. 
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